End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.53 CNY | +1.41% | +3.64% | -12.45% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.45% | 920M | - | ||
+29.53% | 682B | C+ | ||
+30.35% | 586B | B | ||
-3.72% | 364B | C+ | ||
+17.56% | 327B | B- | ||
+3.69% | 285B | C+ | ||
+15.60% | 240B | B+ | ||
+10.16% | 209B | B- | ||
-8.14% | 203B | A+ | ||
+7.10% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603439 Stock
- Ratings GuiZhou SanLi Pharmaceutical Co.,Ltd